Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Paul M Peloso
Do COX-2 Inhibitors Provide Additional Pain Relief and Anti-Inflammatory Effects in Patients With Rheumatoid Arthritis Who Are on Biological Disease-Modifying Anti-Rheumatic Drugs and/or Corticosteroids? Post-Hoc Analyses From a Randomized Clinical Trial With Etoricoxib
BMC Musculoskeletal Disorders
Rheumatology
Orthopedics
Sports Medicine
Related publications
Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients With Rheumatoid Arthritis?
Neurotherapeutics
Neurology
Pharmacology
Differences in Safety of Non-Steroidal Anti-Inflammatory Drugs in Patients With Osteoarthritis and Rheumatoid Arthritis: A Randomized Clinical Trial
Arthritis and Rheumatology
Rheumatology
Allergy
Immunology
OP0281-HPR Preferences of Patients With Rheumatoid Arthritis Regarding Disease Modifying Anti-Rheumatic Drugs: A Discrete Choice Experiment
Efficacy and Safety of Baricitinib for Active Rheumatoid Arthritis in Patients With an Inadequate Response to Conventional Synthetic or Biological Disease‑modifying Anti‑rheumatic Drugs: A Meta‑analysis of Randomized Controlled Trials
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Biological Targets in the Treatment of Rheumatoid Arthritis: A Comprehensive Review of Current and In-Development Biological Disease Modifying Anti-Rheumatic Drugs
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Effect of Disease-Modifying Anti-Rheumatic Drugs on Bone Structure and Strength in Psoriatic Arthritis Patients
Arthritis Research & Therapy
Anti-Inflammatory Drugs for Rheumatoid Arthritis
BMJ
Factors Associated With Quality of Life and Functional Disability Among Rheumatoid Arthritis Patients Treated With Disease-Modifying Anti-Rheumatic Drugs for at Least Six-Months
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental